Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia

NCT05017883 is registered in ClinicalTrials.gov with PersonGen BioTherapeutics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT05017883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05017883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia
Lead sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
July 1, 2021
Completion date
October 31, 2025
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, car